Golden Dome Could Be a Game-Changer for Lockheed, but Valuation and Execution Keep Us Cautious

What happened

The Motley Fool reports that the Golden Dome missile-defense network is a $185 billion program with potential 20-year sustainment of $1.2 trillion, and Lockheed Martin is among three public companies building it. This news aligns with Lockheed's existing strengths in missile defense (THAAD, PAC-3) and could significantly expand its long-term addressable market. However, the DeepValue master report, dated July 2026, rates LMT as WAIT with a base implied value of $605, noting the stock at $582.6 already capitalizes much of the missile-demand story at 21.4x earnings. The report's key near-term catalysts remain funded PAC-3 awards and sustained MFC margins above 14%, with Aeronautics charges a persistent risk. Golden Dome adds a potentially massive future opportunity, but its funding and contract structure are still unclear, and the current valuation leaves little margin of safety.

Implication

Over a multi-year horizon, Lockheed's involvement in Golden Dome could drive substantial revenue and earnings growth if the program proceeds as envisioned. However, the stock already trades at 21.4x earnings with a base scenario implying only modest upside, and near-term execution risks in Aeronautics could offset gains. Therefore, while the long-term story is enhanced, we would wait for either a pullback toward the $545 attractive entry level or concrete evidence of Golden Dome contract awards before increasing exposure.

Thesis delta

The original WAIT thesis emphasized that Lockheed's missile backlog needed to broaden into funded PAC-3 awards and that MFC margins must hold above 14% while Aeronautics charges stopped. The Golden Dome announcement introduces a new, larger potential market for missile defense, which could increase the bull case probability and raise the long-term earnings ceiling. However, because the program is in early stages and funding details are unknown, it does not yet address the near-term execution and valuation concerns that justified the WAIT rating; we maintain WAIT but now view the risk-reward as slightly more favorable for patient investors.